Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
raltitrexed + oxaliplatin + anlotinib + penpulimab
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of the **Ralox regimen** (raltitrexed and oxaliplatin) with **anlotinib** and **penpulimab** is an investigational four-drug chemo-immunotherapy regimen being evaluated for the treatment of unresectable hepatocellular carcinoma (HCC). The regimen combines locoregional/systemic chemotherapy (the Ralox backbone) with anlotinib, a small-molecule multi-target tyrosine kinase inhibitor (TKI) targeting VEGFR, FGFR, PDGFR, and c-Kit, and penpulimab, a humanized anti-PD-1 IgG1 monoclonal antibody. This combination therapy aims to leverage synergistic anti-tumor mechanisms, including DNA damage, thymidylate synthase inhibition, anti-angiogenesis, and immune checkpoint blockade, to improve outcomes in patients with advanced liver cancer. The regimen is currently being studied in a prospective clinical trial led by Nanfang Hospital, Southern Medical University.
- Brand names
- Fukewei
- Other names
- Ralox regimen + anlotinib + penpulimabRalox + anlotinib + penpulimabRaltitrexed + oxaliplatin + anlotinib + penpulimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on raltitrexed + oxaliplatin + anlotinib + penpulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on raltitrexed + oxaliplatin + anlotinib + penpulimab.